Claims for Patent: 6,921,659

Summary for Patent: 6,921,659

Title:	Protease-deficient cells
Abstract:	A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negative bacterial cell is deficient in a chromosomal gene present in a wild-type such cell which gene encodes an aminopeptidase that shares at least 80% sequence identity with the native sequence of aminopeptidase b2324. Either of these types of cells, when comprising a nucleic acid encoding a heterologous polypeptide, produces an N-terminal unclipped polypeptide when it is cultured and the polypeptide recovered, with virtually no N-terminal clipped polypeptide produced as an impurity. Conversely, a method is provided for cleaving an N-terminal amino acid from a polypeptide comprising contacting the polypeptide with an aminopeptidase sharing at least 80% sequence identity with the native sequence of aminopeptidase b2324.
Inventor(s):	John C. Joly
Assignee:	Genentech Inc
Application Number:	US10/243,789

Details for Patent 6,921,659

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006		2022-09-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012		2022-09-12
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016		2022-09-12

International Patent Family for US Patent 6,921,659

Country	Patent Number	Estimated Expiration
South Africa	200401752
World Intellectual Property Organization (WIPO)	03023030
United States of America	7632658